ATLANTA -- The FDA's decision to add a black box warning to the label of clopidogrel (Plavix) came without warning to doctors attending the American College of Cardiology meeting here. But getting the word out to more than 13,000 cardiologists gathered in this city not an easy task.
That challenge as well as the clinical implications of the FDA's action are the subject of a 番茄社区 InFocus™ interview with interventional cardiologist Brian O'Murchu, MD, of Temple University in Philadelphia.
O'Murchu, who is co-chair of the ACC annual sessions planning committee, predicted that the news will travel like "wild fire" through the cardiology community and he expected it the have an immediate impact on clinical practice.